Transdermal delivery of bioidentical progesterone using dutasteride (A 5α-reductase inhibitor): A pilot study

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 4, 2010, Pages 626-636

  Zargar Shoshtari, Sara ^a   Wahhabaghei, Hannaneh ^b   Mehrsai, Abdolrasoul ^b   Wen, Jingyuan ^a   Alany, Raid ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FOLLITROPIN; PLACEBO; PROGESTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SALIVA LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PILOT STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79951779683     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3rw2h     Document Type: Article

References (45)

1. Leonetti HB, Longo S, and Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol, 1999; 94(2):225-228.
2. Azizi G, Hansen A, and Prestwood KM. Effect of micronized progesterone on bone turnover in postmenopausal women on estrogen replacement therapy. Endocr. Res., 2003; 29(2):133-140.
3. Levine H and Watson N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril, 2000; 73(3):516-521.
4. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, and Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: A comparative study. Fertil Steril, 1994; 62(3):485-490.
5. Wren BG, Champion SM, Manga RZ, and Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause, 2003; 10(1):13-18.
6. Lee JR. Osteoporosis reversal with transdermal progesterone. Lancet, 1990; 336(8726):1327.
7. Stanczyk FZ, Paulson RJ, and Roy S. Percutaneous administration of progesterone: Blood levels and endometrial protection. Menopause, 2005; 12(2):232-237.
8. Wren BG, McFarland K, and Edwards L. Micronised transdermal progesterone and endometrial response. Lancet Infectious Diseases, 1999.; 354(9188):1447-1448.
9. Leonetti HB, Wilson KJ, and Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril, 2003; 79(1):221-222.
10. Landes J, Leonetti HB, Steinberg D, and Anasti JN. Transdermal progesterone cream as an alternative progestin in hormone therapy. Alternative Therapies in Health & Medicine, 2005; 11(6):36-38.
11. Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, and Studd J. A double-blind placebocontrolled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause International, 2009; 15(2):63-69.
12. Carey BJ, Carey AH, Patel S, Carter G, and Studd JW. A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women. BJOG: An International Journal of Obstetrics & Gynaecology, 2000; 107(6):722-726.
13. Burry KA, Patton PE, Hermsmeyer K, Weiderman WC, Caillouette JC, Plaut MM, Lamey JR, Holbert T, and Schwartz ML. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol, 1999; 180(6 I):1504-1511.
14. Lewis JG, McGill H, Patton VM, and Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas, 2002; 41(1):1-6.
15. Elshafie MAA and Ewies AAA. Transdermal natural progesterone cream for postmenopausal women: Inconsistent data and complex pharmacokinetics. J. Obstet. Gynaecol., 2007; 27(7):655-659.
16. Stevenson JC and Purdie DW. Use of Pro-Gest cream in postmenopausal women. Lancet, 1998; 352(9131):905-906.
17. Haukkamaa M, Laurikka-Routti M, and Heikinheimo O. Transdermal absorption of the progestin ST-1435: Therapeutic serum steroid concentrations and high excretion of the steroid in saliva. Contraception, 1991; 44(3):269-276.
18. Thigpen AE and Russell DW. Four-amino acid segment in steroid 5alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem, 1992; 267(12):8577-8583.
19. Chen W, Thiboutot D, and Zouboulis CC. Cutaneous androgen metabolism: Basic research and clinical perspectives. J. Invest. Dermatol., 2002; 119(5):992-1007.
20. Wiebe JP, Souter L, and Zhang G. Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol, 2006; 100(4-5):129-140.
21. Penotti M, Fabio E, Modena AB, Rinaldi M, Omodei U, and Vigano P. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril, 2003; 79(5):1112-1117.
22. Wong TY, Koh D, Wee A, Ng V, Koh YT, Sum Z, and Koh G. The effect of cotton-based collection methods on eosinophil cationic protein (ECP) concentrations detected in saliva. Journal of Asthma and Allergy, 2008; 1):45-48.
23. Strazdins L, Meyerkort S, Brent V, D'Souza RM, Broom DH, and Kyd JM. Impact of saliva collection methods on sIgA and cortisol assays and acceptability to participants. J. Immunol. Methods, 2005; 307(1-2):167-171.
24. Lewis JG. Steroid analysis in aaliva: an overview. Clin. Biochem. Rev., 2006; 27(3):139-146.
25. Missmer SA, Eliassen AH, Barbieri RL, and Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl. Cancer Inst., 2004; 96(24):1856-1865.
26. North American Menopause S. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause, 2004; 11(1):11-33.
27. Ram PA and Waxman DJ. Pretranslational control by thyroid hormone of rat liver steroid 5a- reductase and comparison to the thyroid dependence of two growth hormone-regulated CYP2C mRNAs. J Biol Chem, 1990; 265(31):19223-19229.
28. Judd HL, Shamonki IM, Frumar AM, and Lagasse LD. Origin of Serum Estradiol in Postmenopausal Women. Obstet Gynecol, 1982; 59(6):680-686.
29. Stanczyk FZ, Paulson RJ, and Roy S. Percutaneous administration of progesterone: Blood levels and endometrial protection. Menopause., 2005; 12(2):232-237.
30. Wren BG, McFarland K, Edwards L, O'Shea P, Sufi S, Gross B, and Eden JA. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric, 2000; 3(3):155-160.
31. O'Leary P, Feddema P, Chan K, Taranto M, Smith M, and Evans S. Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to preand postmenopausal women. Clin. Endocrinol., 2000; 53(5):615-620.
32. Cooper A, Spencer C, Whitehead MI, Ross D, Barnard GJR, and Collins WP. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet, 1998; 351(9111):1255-1256.
33. Southwell D, Barry BW, and Woodford R. Variations in permeability of human skin within and between specimens. Int. J. Pharm., 1984; 18(3):299-309.
34. Mauvais-Jarvis P, Baudot N, and Bercovici JP. In vivo studies on progesterone metabolism by human skin. Journal of Clinical Endocrinology and Metabolism, 1969; 29(12):1580-1585.
35. Wang DY and Knyba RE. Salivary progesterone: Relation to total and non-protein-bound blood levels. J Steroid Biochem Mol Biol, 1985; 23(6A):975-979.
36. Evans J. Progesterone in saliva does not parallel unbound progesterone in plasma. Clinical Chemistry, 1986; 32(3):542-544.
37. Celec P, Ostatnikova D, Skokoova M, Hodosy J, Putz Z, and Kudela M. Salivary sex hormones during the menstrual cycle. Endocr. J., 2009; 56(3):521-523.
38. Kaufman E and Lamster IB. The diagnostic applications of saliva--a review. Critical Reviews in Oral Biology & Medicine, 2002; 13(2):197-212.
39. Koefoed P and Brahm J. The permeability of the human red cell membrane to steroid sex hormones. Biochimica et Biophysica Acta - Biomembranes, 1994; 1195(1):55-62.
40. Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci Jr ML, and Bertino Jr JS. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J. Clin. Pharmacol., 2005; 45(6):614-619.
41. Sites CK. Bioidentical hormones for menopausal therapy. Women's Health, 2008; 4(2):163-171.
42. Boothby LA, Doering PL, and Kipersztok S. Bioidentical hormone therapy: A review. Menopause, 2004; 11(3):356-367.
43. Cirigliano M. Bioidentical hormone therapy: A review of the evidence. Journal of Women's Health, 2007; 16(5):600-631.
44. Laine MA and Ojanotko AO. Progesterone metabolism in human saliva in vitro. The Journal of Steroid Biochemistry and Molecular Biology, 1999; 70(1-3):109-113.
45. Elattar TMA. Metabolism of estrone and progesterone in vitro in human saliva. J Steroid Biochem, 1975; 6(10):1455-1458.